A combination of zidovudine, didanosine, and lamivudine was used to treat 10 patients with primary human immunodeficiency virus type 1 (HIV-1) infection 5 -28 days after the onset of symptoms. When therapy began, the mean plasma HIV-1 RNA level was 5.31 { 0.33 log 10 copies/ mL and the mean CD4 T cell count was 630 { 112 1 10 6 /L. The plasma HIV-1 RNA level decreased rapidly, and levels dropped below the cutoff in each case after 108 { 32 days. Lymph nodes from 5 patients were biopsied before therapy and during follow-up. Infectious HIV-1 could not be cultivated from any lymph node mononuclear cells taken on day 90, and HIV-1 RNA was at very low levels in lymph nodes after 1 year. In some cases, waning of the antibody response to HIV-1 was shown by Western blot after several months of undetectable plasma RNA. These data demonstrate that triple-drug therapy has a potent antiviral effect during primary HIV-1 infection.
The plasma level of human immunodeficiency virus type
Patients and Methods 1 (HIV-1) RNA is recognized as a major prognostic factor when a burst of viremia disseminates the virus throughout Diagnostic Biotechnology, Singapore), or a positive blot with a the body [2] . Therapeutic intervention during PHI is intended negative test during the preceding 3 months. After an initial blood to reduce this dissemination and decrease the level of the evaluation and, in 4 cases, surgical lymph node biopsy, the patients steady state, to improve the clinical course of the patients were given oral zidovudine (200 mg three times daily) plus dida- [3] . This intervention should transform their evolution, maknosine (ddI, 200 mg twice daily) plus lamivudine (3TC, 150 mg ing them similar to patients with long-term nonprogressive twice daily). Therapy began 5 days after the first symptoms of PHI in 1 patient, 10 days in 4, 15 days in 1, and 28 days in 4.
HIV-1 infection, who have a low virus load and intact lymph
Serum from the first days of the symptoms was analyzed retrospecnode architecture. However, the limited number of antirettively for these last 4 patients, and Western blot results were inderoviral agents available until recently has permitted only terminate. trials with single drugs or combinations of two drugs, and CD4 T cell counts. The CD4 T cell count was measured by these have had only modest antiviral effects [3 -5] . We adflow cytometry (EpicsProfile; Coulter) using commercially availministered a triple-drug combination to 10 patients presentable monoclonal antibodies (Dako, Trappes, France).
ing with PHI with the aim of assessing HIV-1 replication in Plasma HIV-1 RNA. Plasma HIV-1 RNA levels were meablood and lymph nodes during therapy. This report describes sured at the first visit and at regular intervals thereafter, using a the preliminary results of this pilot study, some patients polymerase chain reaction technique (Amplicor Monitor HIV-1; Roche Diagnostic Systems, Neuilly sur Seine, France). The cutoff having reached 1 year of therapy with a virologic evaluation value of this test for plasma is 200 copies/mL. When levels below of lymphoid reservoirs at that time.
this cutoff were obtained with therapy, the method was made more sensitive by increasing the sample size to 500 mL and the number of amplification cycles to 40. This procedure gave an analytic sensitivity approaching 20 copies/mL [6] (unpublished data). sion analysis, the rates of RNA decrease were similar both syncytium-inducing (SI) or non-SI (NSI) HIV-1 was tested on MT-2 cells as described previously [9] .
before and after therapy in these patients ( figure 1B) . patients were negative for HIV-1 RNA. In fact, very low levels could be detected in these 3 lymph nodes without any dilution We studied 5 men and 5 women (mean age { SE, 31 { 3 years). HIV-1 infection had been acquired by homosexual acof the sample (table 1) , as is necessary when high titers are present [8] . HIV-1 RNA was also quantified in the patient with tivity in 4 cases, heterosexual transmission in 5, and intravenous drug use in 1. The mean CD4 T cell count was 630 { an SI phenotype by four sequential needle biopsies of lymph nodes during the 4 months after initiation of the triple-drug 112 1 10 6 /L when therapy began, and the mean plasma HIV RNA level was 5.31 { 0.33 log 10 copies/mL. At the first bioregimen. The amount of HIV-1 RNA in lymph nodes decreased exponentially in this patient, with a mean half-life of 15.75 logic evaluation before antiretroviral therapy (1 -2 days before treatment began), the mean infectious HIV-1 titer in PBMC days (95% confidence interval, 14.14 -17.77). Infectious virus could not be cultivated from the PBMC of was 58 { 11 IU/10 6 cells. In 5 patients, the first symptoms of PHI began Ç1 week before admission and therapy was initiated any patient 1 -4 months after therapy, and there was no cellular viremia during the follow-up in all cases. The amount of proviwithin the 2 days following confirmation of the diagnosis. For 1 patient, diagnosis was established 7 days after the onset of ral DNA in PBMC was measured in 4 patients. Titers declined initially, then stabilized, except for 1 patient, who had a transymptoms, but the patient was referred to the hospital only 1 week later. For 4 patients, the general practitioners waited to sient increase. The amount of proviral DNA was at the limit of detection after 1 year in 1 patient (figure 1C). have 2 Western blot assays confirming HIV infection before sending the patients to the hospital; therapy was initiated Ç28
The number of CD4 T cells tended to increase with therapy, reaching /243 1 10 6 /L after 4 months, and the number of days after the first symptoms. Patients treated before 15 days after the onset of symptoms tended to have a higher virus load CD8 T cells tended to decrease. Consequently, a significant increase (paired t test, P õ .05) in the mean CD4:CD8 ratio in plasma than others did, but the difference was not statistically significant (mean, 5.67 { 0.56 vs. 4.94 { 0.34 log 10 copies/ was observed after 2 months of therapy ( figure 1D ). Samples from patients who were treated before day 15 of mL; P Å .30). This could be because, although the HIV-1 RNA levels were ú1.2 1 10 6 copies/mL in 4 of these 5 patients, the symptoms were negative by Western blot (1 patient) or were weakly positive for gp160 and p25 only (4 patients) at the last patient (patient 1) had only 2593 copies/mL. This woman attended the sexually transmitted disease clinic because of sexstart of the combination regimen. None developed a serologic response to all proteins during follow-up. Three patients reual contact with an intravenous drug user with HIV-1 infection and presented with minor symptoms (sore throat) of PHI. The mained seronegative for gp41, p66, p39, and p17 at 6 months. One patient remained seronegative for gp41, p66, p39, and p31 first plasma and/or PBMC virus isolate before therapy was NSI in 9 patients and SI in 1.
at 10 months and then became negative for p17, p51, and p55. The Western blot of patient 1 showed more positive bands until The plasma HIV-1 RNA levels of all patients decreased dramatically after initiation of therapy ( figure 1A ) and dropped the third month, and then gradually lost some seroreactivity. At 14 months, this patient was clearly positive for only gp160 below the cutoff of 200 copies/mL after a mean of 108 { 32 days. Undetectable plasma levels were obtained after 54 { 18 (figure 2). The HIV-1 Western blot showed all bands within a few weeks after initiation of therapy in 2 patients treated after days in patients treated before day 15 of symptoms and after / 9d27$$my26 02-28-97 15:36:59 jinfas UC: J Infect day 15 of symptoms and lacked only p66 positivity in the 3 appeared to be the most potent triple-drug regimen when this protocol was initiated (before protease inhibitors became availothers. One of these patients became seronegative for p17, p39, p55, and gp41 after 10 months of therapy. There were no able in France). However, this combination is still under investigation in large-scale trials, and no data are available to comchanges during follow-up for the other patients.
The mean follow-up for these 10 patients was 10.7 { 1.3 pare this regimen with triple-drug combinations that include a protease inhibitor. The 10 patients with PHI described here all months. The antiretroviral therapy for all patients had been uninterrupted, and no patient developed toxicity, except for had major reductions in plasma HIV-1 RNA levels after the start of therapy, reaching at least 05 log 10 in some patients severe nausea and diarrhea in 1 during the first 2 months.
whose virus load decreased to õ20 copies/mL. As we do not have a control group, it is not possible to determine the relative Discussion contribution of therapy, immune responses, and loss of target cells in this decrease. However, in ú60 untreated primary HIVThe combination of zidovudine, ddI, and 3TC was used, as it can block HIV-1 replication completely in vitro [11] and infected patients tested so far, viremia remained detectable at / 9d27$$my26 02-28-97 15:36:59 jinfas UC: J Infect is still limited, although there were too few patients in our ‡ RNA copies/10 5 cells. study for statistical significance to be reached.
The 4 patients from whom samples were obtained before diagnosis showed similar rates of virus decline before and after levels of 10 3 -10 7 HIV-1 RNA copies/mL [4] . In the trial of therapy. Early therapy during PHI possibly works mainly by zidovudine versus placebo that involved patients treated after decreasing viral dissemination in the body and preventing the 25.1 days (mean) following the onset of symptoms of PHI establishment of a steady state in plasma [14] . [4] , plasma HIV-1 RNA titers decreased by 1.44 log 10 in the The changes in the serologic markers of HIV-1 infection in zidovudine group and by 0.93 log 10 in the placebo group after patients with very early therapeutic intervention are striking. 6 months, but the difference was not statistically significant.
Patients receiving early intervention did not show seroreactivity In another study of 24 patients with PHI, plasma HIV-1 titers by Western blot to all proteins, and some bands disappeared decreased by Ç2 log 10 without therapy 3 -12 months after the after several months of therapy. The exact significance of this acute syndrome [2] . The lymph node biopsies from 4 patients waning antibody response, which was also recently reported just before therapy showed high titers of infectious virus and by Perrin et al. [15] and Markowitz et al.
[16], is not clear but proviral DNA in LNMC during the acute phase, confirming could be related to the complete inhibition of HIV-1 replication. the very early establishment of HIV-1 infection in lymphoid
The declining antibody response was observed only in patients tissues. The decrease in plasma HIV-1 replication was generwhose plasma HIV-1 RNA remained at õ20 copies/mL. ally associated with a decrease in lymph node virus load, as
The changes in the lymphocyte subsets of our patients showed an increase in the CD4 cell subset and a decrease in infectious virus was no longer cultivated from LNMC from 
